Agila, Bio-XCell Plan $34.4 Million R&D, Drug-Making Facility In Malaysia
This article was originally published in PharmAsia News
Executive Summary
Strides Arcolab's Agila Biotech unit in Malaysia and Bio-XCell have signed an agreement to build a customized biotech facility in Malaysia for $34.4 million.